Enable technology and product development. Hangzhou Just Biotherapeutics will accomplish its long-term mission of increasing global access to important biologics through strategic technology and product partnerships.

We are proud of the significant work accomplished with our current partners to build a solid technology infrastructure at Hangzhou Just Biotherapeutics. We are now actively looking for product partnerships that leverage our strengths for delivering meaningful therapeutics to a global marketplace.  
–Dr. Jonathan Zhao, Co-Founder & CEO of Hangzhou Just Biotherapeutics


Just and Hangzhou Just Biotherapeutics are sisiter companies, sharing the same mission of designing and applying innovative technologies to provide biotherapeutics to a global population.

Just was founded in 2014 in Seattle and has a team of approximately 70 specialists and research engineers. The leadership team has an average of 25 years of experience in biologics design, process engineering and production of complex biologics. Over the past 30 years, members of the team have facilitated the filing and development of several products and expanded multiple biologics factories.

Lilly Asia Ventures

Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth. sharing the same mission of designing and applying innovative technologies to provide biotherapeutics to a global population.

ARCH Venture Partners

ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.

G-CON Manufacturing

G-CON Manufacturing founded in 2009 designs, produces and installs prefabricated, autonomous cleanroom Pod® . G-CON’s cleanroom Pod® portfolio encompasses a variety of different dimensions and purposes, from laboratory environments to personalized medicine and production process platforms.

Just and G-CON Manufacturing are working together on Hangzhou Just Biotherapeutics state of the art biologics facility. In this application, G-CON Pod will be referred to as Pod™, representing the fully equipped processing units capable of running highly intensified bioprocesses. By creating Pod™, we are able to integrate molecular and process technologies into a highly efficient design, achieving low- cost, flexible and deployable manufacturing.


Incorporated in 1974, Temasek is an investment company headquartered in Singapore. Supported by 10 offices internationally, Temasek owns a S$275 billion (US$197 billion, €184 billion, £158 billion, RMB1.35 trillion)* portfolio as at 31 March 2017, mainly in Singapore and the rest of Asia.

Its portfolio covers a broad spectrum of industries: financial services; telecommunications, media & technology; transportation & industrials; consumer & real estate; life sciences & agribusiness; as well as energy & resources. Temasek's investment activities are guided by four investment themes and the long term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions.


Founded in 1996, Taikang is a large insurance and financial service conglomerate. The company operates through three main businesses: insurance, asset management and health and elderly care.

Taikang Insurance Group has a number of subsidiaries which include Taikang Life, Taikang Asset, Taikang Pension, Taikang Community, Taikang Health and Tk.cn. Its business scope covers a wide range of fields, such as life insurance, pension, enterprise annuity, online property and casualty insurance, asset management, health and elderly care, health management, commercial real estate and offshore businesses. Taikang has provided services to 185,000,000 customers over the past 20 years. It has been on the Top 500 Enterprises for 13 years.

Hillhouse Capital

Hillhouse Capital Group (Hillhouse) is a company dedicated to long-term value investing. Founded by Lei Zhang in 2005, it has grown to be China’s biggest private equity investment company. Hillhouse focuses on the healthcare, consumer, TMT, advanced manufacturing, finance and corporate services sectors, and has invested in many household names in China including Tencent, Baidu, JD.com, Midea, Blue Moon, Belle International and Nio.

Bio-pharmaceuticals and healthcare has always been one of our most important areas of investment. Aiming to be a long-term partner with companies developing innovative medicine, Hillhouse has invested in and supported a number of medical enterprises, including Wuxi Apptec, BeiGene, Gan & Lee Pharmaceuticals, Shanghai Junshi Biosciences, Innovent Biologics and Zhejiang Hisun Pharmaceutical. In Europe and the United States, we have invested in Moderna, Viela, Kiniksa, Apellis and Arcus, among other dozens of biotechnology and pharmaceutical companies.

908 Devices

908 Devices is setting off a revolution in how chemical analysis gets done. We offer point-of-need chemical and biomolecular analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These purpose-built and user-centric devices serve the life science, field forensics and other applied markets. 908 Devices is headquartered in the heart of Boston where we research, design and manufacture innovative products based on high-pressure mass spectrometryTM (HPMS) and microfluidic separation technology.

Interested partner or investor? Please contact us at media@justbiochina.com for more information.